| Michael R Myers, CRNA | |
|
14914 67th St Ne, Grafton, ND 58237-9206 | |
| (701) 352-3604 | |
| (701) 352-3604 |
| Full Name | Michael R Myers |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 14914 67th St Ne, Grafton, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457387391 | NPI | - | NPPES |
| ND200189 | Other | ND | LHS/BANNERHEALTH # |
| 86D19MY | Other | MN | MNBS # |
| 937254 | Other | MN | AMERICA'S PPO/ARAZ # |
| 952526200 | Medicaid | MN | |
| DAP021026986 | Other | MN | PREFERRED ONE # |
| HP38638 | Other | MN | HEALTHPARTNERS # |
| 169230 | Other | MN | UCARE # |
| 19063 | Other | MN | NDBS # |
| 2000780 | Other | MN | MEDICA # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R121975-1 (Minnesota) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | R19657 (North Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael R Myers, CRNA 14914 67th St Ne, Grafton, ND 58237-9206 Ph: (701) 352-3604 | Michael R Myers, CRNA 14914 67th St Ne, Grafton, ND 58237-9206 Ph: (701) 352-3604 |
News Archive
BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the European launch of its new, unified platform pacemaker series, Evia, and several new products to further strengthen its bradycardia portfolio.
A new research study has revealed an important relationship between proteins secreted by the heart and obesity, glucose intolerance, and insulin resistance. The findings, published today in Obesity, offer a new approach to treating metabolic disorders, including type 2 diabetes, by targeting the pathway that controls the proteins' concentration in the blood.
HAVING radiotherapy once a day for six and a half weeks or twice a day for three weeks - when combined with chemotherapy - is equally good at treating small cell lung cancer that hasn't spread.
Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted a Breakthrough Therapy designation to cyclic pyranopterin monophosphate (cPMP, or ALXN1101), an enzyme co-factor replacement therapy for the treatment of patients with molybdenum cofactor deficiency type A, a severe and life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic damage within the first weeks of life.
› Verified 2 days ago